Physicians' Academy for Cardiovascular Education

Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure

Meeting report with video, highlights and slides of a PACE-CME symposium held during ESC 2018 in Munich on the potential role of SGLT2 inhibition in clinical cardiology

Summary | Changing focus in diabetes: From glucose to CV risk management

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Stephan Jacob, in which he talked about the management of diabetes, focusing on the shift from glucose to CV risk management in patients with diabetes.

Summary | SGLT2 inhibition in cardiology: What is the profile of benefit?

Munich, Berlin - August 27, 2018

This is a summary of the presentation by prof. Nikolaus Marx, in which he addressed the mode of action of SGLT2 inhibitors, and presented clinical outcome data and potential mechanisms.

SGLT2 inhibition in cardiology: What is the profile of benefit?

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Nikolaus Marx, MD - Aachen, Germany
Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Prof. Marx summarizes the findings of recently published CV outcome trials with SGLT2 inhibitors and discusses potential mechanisms explaining the CV effects of SGLT2 inhibitors in patients with T2DM at high CV risk.

Changing focus in diabetes: From glucose to CV risk management

10' education - Aug. 27, 2018 - ESC 2018 - Munich, Germany - Stephan Jacob, MD - Villingen-Schwenningen, Germany
Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Prof. Jacob gives an overview of new antidiabetic interventions that showed a reduction in CV and total mortality in CV risk patients, which seems to be independent of improved glycemic control.

Slides: Heart failure & SGLT2: With or without diabetes?

Presentation Prof. John McMurray

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - John McMurray, Glasgow, UK
This lecture by prof. John McMurray was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: Changing focus in diabetes: From glucose to CV risk management

Presentation Prof. Stephan Jacob

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Stephan Jacob, MD – Villingen - Schwenningen, Germany
This lecture by prof. Stephan Jacob was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Slides: SGLT2 inhibition in cardiology: What is the profile of benefit?

Presentation Prof. Nikolaus Marx

Slides (presentation) - Aug. 27, 2018 - ESC Congress 2018, Munich - Nikolaus Marx, MD - Aachen, Germany
This lecture by prof. Nikolaus Marx was part of a CME accredited symposium

Slides as educational service to PACE members and meeting participants

Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure
Targeting SGLT2 in Clinical Cardiology: Exploring the Benefits in CV risk, Diabetes & Heart Failure